PriceTargets.com logo

Centessa Pharmaceuticals - CNTA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.70
  • Forecasted Upside: 51.99%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 2 Strong Buy Ratings
$24.80 As of 12/19/2025 04:58 PM ET
▼ -0.046 (-0.19%)

This chart shows the closing price for CNTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Centessa Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNTA

Analyst Price Target is $37.70
▲ +51.99% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Centessa Pharmaceuticals in the last 3 months. The average price target is $37.70, with a high forecast of $62.00 and a low forecast of $27.00. The average price target represents a 51.99% upside from the last price of $24.80.

This chart shows the closing price for CNTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 13 polled investment analysts is to buy stock in Centessa Pharmaceuticals. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 2 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/19/2025
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025

Latest Recommendations

  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2025OppenheimerBoost TargetOutperform ➝ Outperform$40.00 ➝ $62.00
12/1/2025B. RileyBoost TargetBuy ➝ Buy$33.00 ➝ $42.00
11/19/2025Chardan CapitalUpgradeStrong-Buy
11/18/2025GuggenheimBoost TargetBuy ➝ Buy$28.00 ➝ $43.00
11/13/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$30.00 ➝ $35.00
11/7/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$31.00 ➝ $30.00
11/5/2025Truist FinancialSet Target$30.00
10/28/2025StephensInitiated CoverageOverweight$35.00
10/28/2025StephensInitiated CoverageOverweight$35.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/6/2025GuggenheimReiterated RatingBuy ➝ Buy$28.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/3/2025Lifesci CapitalUpgradeStrong-Buy
9/3/2025Wells Fargo & CompanyInitiated CoverageOverweight$31.00
8/29/2025OppenheimerInitiated CoverageOutperform$40.00
8/12/2025Chardan CapitalReiterated RatingBuy ➝ Buy$30.00
7/30/2025Chardan CapitalReiterated RatingBuy ➝ Buy$30.00
7/21/2025Truist FinancialInitiated CoverageBuy$30.00
5/28/2025Needham & Company LLCInitiated CoverageBuy$35.00
5/8/2025OppenheimerInitiated CoverageOutperform ➝ Outperform$6.00
5/8/2025Chardan CapitalInitiated CoverageBuy$30.00
3/31/2025Piper SandlerInitiated CoverageOverweight$38.00
3/26/2025GuggenheimReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/7/2025Morgan StanleyReiterated RatingOverweight$27.00 ➝ $27.00
2/10/2025GuggenheimReiterated RatingBuy ➝ Buy
1/7/2025TD CowenInitiated CoverageBuy
11/15/2024GuggenheimBoost TargetBuy ➝ Buy$24.00 ➝ $28.00
9/19/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$11.00 ➝ $26.00
9/19/2024B. RileyInitiated CoverageBuy$33.00
9/16/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$20.00 ➝ $35.00
9/11/2024GuggenheimBoost TargetBuy ➝ Buy$20.00 ➝ $24.00
9/11/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$13.00 ➝ $19.00
9/9/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$15.00 ➝ $20.00
8/14/2024OppenheimerReiterated RatingOutperform ➝ Outperform$14.00 ➝ $14.00
7/18/2024OppenheimerInitiated CoverageOutperform$14.00
6/21/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.00
4/1/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$15.00
11/15/2023Jefferies Financial GroupUpgradeHold ➝ Buy$4.00 ➝ $11.00
10/26/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$4.00 ➝ $8.00
8/15/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$4.50 ➝ $5.00
8/15/2023GuggenheimBoost TargetBuy ➝ Buy$9.00 ➝ $10.00
8/15/2023SVB SecuritiesBoost TargetOutperform ➝ Outperform$6.00 ➝ $11.00
7/25/2023BMO Capital MarketsBoost TargetOutperform$11.00 ➝ $15.00
6/21/2023Evercore ISIInitiated CoverageOutperform
6/12/2023GuggenheimInitiated CoverageBuy$9.00
3/17/2023Leerink PartnersReiterated RatingOutperform$6.00
3/17/2023SVB SecuritiesInitiated CoverageOutperform$6.00
1/24/2023Morgan StanleyLower TargetUnderweight$5.00 ➝ $4.00
8/12/2022Morgan StanleyDowngradeOverweight ➝ Underweight$10.00 ➝ $5.00
8/11/2022BMO Capital MarketsLower Target$19.00 ➝ $11.00
8/11/2022The Goldman Sachs GroupLower TargetNeutral$5.00 ➝ $4.00
7/15/2022Morgan StanleyLower TargetOverweight$15.00 ➝ $10.00
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$19.00
6/3/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$4.00
5/24/2022The Goldman Sachs GroupLower TargetNeutral$12.00 ➝ $8.00
5/24/2022Morgan StanleyLower TargetOverweight$19.00 ➝ $15.00
4/5/2022Morgan StanleyLower TargetOverweight$20.00 ➝ $19.00
2/11/2022The Goldman Sachs GroupInitiated CoverageNeutral$12.00
6/22/2021Jefferies Financial GroupInitiated CoverageBuy$35.00
6/22/2021Morgan StanleyInitiated CoverageOverweight$37.00
6/22/2021The Goldman Sachs GroupInitiated CoverageBuy$42.00
(Data available from 12/19/2020 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 40 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2025
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2025
  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2025
  • 12 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 27 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 13 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 20 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025

Current Sentiment

  • 20 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Centessa Pharmaceuticals logo
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Read More

Today's Range

Now: $24.80
Low: $24.17
High: $25.28

50 Day Range

MA: $25.78
Low: $22.12
High: $29.91

52 Week Range

Now: $24.80
Low: $9.60
High: $30.58

Volume

582,981 shs

Average Volume

1,159,459 shs

Market Capitalization

$3.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Centessa Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Centessa Pharmaceuticals in the last twelve months: B. Riley, Chardan Capital, Guggenheim, Lifesci Capital, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings, Inc., Piper Sandler, Stephens, TD Cowen, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for CNTA.

What is the current price target for Centessa Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Centessa Pharmaceuticals in the last year. Their average twelve-month price target is $37.70, suggesting a possible upside of 52.0%. Oppenheimer Holdings, Inc. has the highest price target set, predicting CNTA will reach $62.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $27.00 for Centessa Pharmaceuticals in the next year.
View the latest price targets for CNTA.

What is the current consensus analyst rating for Centessa Pharmaceuticals?

Centessa Pharmaceuticals currently has 1 sell rating, 10 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNTA will outperform the market and that investors should add to their positions of Centessa Pharmaceuticals.
View the latest ratings for CNTA.

What other companies compete with Centessa Pharmaceuticals?

Other companies that are similar to Centessa Pharmaceuticals include Viatris, Summit Therapeutics, Ascendis Pharma A/S, Dr. Reddy's Laboratories and Moderna. Learn More about companies similar to Centessa Pharmaceuticals.

How do I contact Centessa Pharmaceuticals' investor relations team?

Centessa Pharmaceuticals' physical mailing address is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. The company's listed phone number is 44-73-9178-9784 and its investor relations email address is [email protected]. The official website for Centessa Pharmaceuticals is www.centessa.com. Learn More about contacing Centessa Pharmaceuticals investor relations.